01324-6/asset/4a54a807-9d4c-43b0-9cee-525570c8c25d/main.assets/gr2_lrg.jpg)
tirzepatide surpass-5 Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Efficacy and Safety of Tirzepatide
Description
Mounjaro vs
Recognizing the signs that warrant professional help can make all the difference
The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk [19]
Does exactly what the description says
Weight loss typically accelerates during this phase
